EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Nir Peled
Meta Tag
Speaker Nir Peled
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
salvage strategy
metastatic non-small cell lung cancer
EGFR targeted therapy
EGFR TKI treatment
common EGFR mutations
EGFR exon 20 mutations
objective response rate
duration of therapy
progression-free survival
Powered By